Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

Tue, 25th May 2021 17:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Webis Holdings PLC - Isle of Man-based gaming firm - Receives West Virginia wagering license which allows company to accept online wagers from state residents. "We are delighted to receive this license from the West Virginia Racing Commission for WatchandWager. We believe that this license will be mutually beneficial to both the company and the state in the forms of revenue and taxes generated from wagering," says Webis.

----------

Revolution Bars Group PLC - bars operator based in Ashton-under-Lyne, England - Intends to raise GBP21.0 million via a firm placing, placing and an open offer at 20 pence per share. Says proceeds will go towards indebtedness, accelerate its existing site refurbishment programme and to take advantage of favourable market conditions for estate expansion.

----------

JPMorgan Global Core Real Assets Ltd - real estate, transportation and infrastructure investor - Says further USD13.8 million of committed capital called, with a funding date no later than June 7. "This capital is being called by the Asia-Pacific Real Estate Strategy and materially increases the exposure to industrial/ logistics assets within the property allocation," says JPMorgan Global Core. Says it has now invested 96% of the total capital raised from proceeds of both the IPO and all subsequent share issuance.

----------

Tiziana Life Sciences PLC - London-based therapeutics for oncology, inflammation and infectious diseases - Says the first patient with secondary progressive multiple sclerosis was dosed with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody. Says this is the first-ever clinical study in SPMS patients, under an individual patient expanded access IND, and will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. "Effective and targeted treatments for progressive MS are urgently needed. Nasal Foralumab could revolutionize treatment for this disabling form of disease," says Tanuja Chitnis, professor of neurology at Harvard Medical School.

----------

Mothercare PLC - Hemel Hempstead, England-based retailer to parents and young children - Reports unaudited net worldwide sales of GBP326 million for the year to March 27, down 40% to a year prior, impacted by varied approaches to Covid-19 in franchisee markets. "As a global brand the impact of Covid-19 has varied enormously by market as the countries in which our franchise partners operate have addressed the Covid-19 pandemic in many different ways including, but not limited to, restrictions on travel, movement and operating hours of retailers. These issues have been compounded by similar restrictions for our manufacturing partners, which coupled with the disruption to the global movement of freight, have caused additional challenges with availability of product for franchise partners further impacting sales for the year," says Mothercare. Expects to report a "small" earnings before interest, depreciation and amortisation profit for the year. Sees annual operating profit of GBP15 million "in future years" .

----------

Custodian REIT PLC - Leicester, England-based commercial real estate investor - Sells retail unit in Nottingham at auction for GBP700,000, in line with the most recent valuation. Says the disposal has reduced the Company's high street retail sector weighting by income from 10% to 9%. "This asset was not aligned with the strategy of the Company as we did not anticipate future rental recovery," says Custodian.

----------

Baillie Gifford UK Growth Fund PLC - investment firm focused on capital growth over the long-term from investment primarily in shares of listed UK companies - Announces name change to Baillie Gifford UK Growth Trust, effective Wednesday. The trading symbol and ISIN are to stay the same.

----------

Octopus Titan VCT PLC - venture capital trust - Announces that terms have been agreed for Snap Inc to acquire WaveOptics Ltd "at a value not materially different from its holding value". WaveOptics is a business that designs and sells a set of components for use in augmented reality glasses that allow for the creation of AR displays. Titan gas invested around GBP16.0 million in WaveOptics.

----------

IronRidge Resources Ltd - Australia-based minerals exploration company - Reports additional broad and high-grade lithium pegmatite drill intersections at new targets adjacent to the Ewoyaa lithium project in Ghana. "We are highly encouraged with the ongoing results received, which continue to confirm additional high grades in new exploration targets tested within the ELP area," says IronRidge.

----------

Sareum Holdings PLC - Cambridge-based drug development firm - Says Covid-19 continues to impact the contract research organisations with which Sareum is working to complete the preclinical development of SDC-1801 for autoimmune disease. "While initially the impact on development timelines was minimal, it has increased and is causing further delays to the conduct of the final preclinical studies the company needs to complete on SDC-1801 prior to filing an exploratory Clinical Trial Application," says Sareum. Says it now expects final toxicity and safety studies to complete in the third quarter of the year.

----------

Epwin Group PLC - Solihull, England-based building products manufacturer - Says demand from the group's key markets continues to be high, with indicators of consumer confidence strengthening. Revenue for the first four months of the year are 56% ahead of 2020, which included the first lockdown period, and 9% ahead of 2019. "The outlook for the current year continues to be favourable, notwithstanding the raw material cost inflation and supply chain issues, which we are managing proactively. The medium and long-term drivers for the Group's markets also remain positive, with a shortage of housing, an ageing and underinvested housing stock, as well as environmental and safety concerns driving legislation and initiatives that will require improvements to homes on a larger scale than just essential maintenance," says Epwin.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Dec 2019 15:38

Tiziana initiates study of 'Foralumab' in coated capsule form

(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.

Read more
4 Dec 2019 11:52

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Read more
20 Nov 2019 13:02

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Read more
1 Nov 2019 17:31

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Read more
30 Sep 2019 10:27

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Read more
16 Sep 2019 13:03

Tiziana Life Sciences Gets New Foralumab Formulation US Trial Approval

(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in

Read more
10 Sep 2019 14:34

Tiziana Life Sciences Announces Positive Data From Foralumab Trial

(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a

Read more
4 Sep 2019 11:04

Encouraging Data From Tiziana Life Sciences Milciclib Cancer Study

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in

Read more
22 Jul 2019 09:54

Tiziana Reports No Drug-Related Deaths In Milciclib Liver Cancer trial

(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6

Read more
1 Jul 2019 10:49

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith,

Read more
1 Jul 2019 10:20

Tiziana Notes Positive Study Of Drug Similar To Foralumab In Diabetes

(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company

Read more
1 May 2019 10:08

FDA asks Tiziana for more information on next 'foralumab' trial

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.

Read more
24 Apr 2019 12:20

Most Patients Stick With Milciclib In Tiziana Life Sciences Study

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were -

Read more
4 Apr 2019 10:58

Tiziana Life Sciences Annual Loss Narrows On Marginally Reduced Costs

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted

Read more
20 Mar 2019 13:01

Tiziana Life Sciences Submits Application For Foralumab Trial In US

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it has submitted an application in the US to begin a phase one trial of its autoimmune and inflammatory disease drug new drug a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.